Clinical Trial: Cognitive Therapy for Recurrent Depression

This study is currently recruiting patients.

Sponsored by: National Institute of Mental Health (NIMH)
Information provided by: National Institute of Mental Health (NIMH)


This study will determine the effectiveness of cognitive therapy (CT) in people who have had a depressive episode.
Condition Intervention
 Behavior: Cognitive therapy
 Drug: Antidepressants

MedlinePlus related topics:  Depression

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Efficacy Study

Official Title: Prophylactic Cognitive Therapy for Depression.

Further Study Details: 
Primary Outcomes: Depressive relapse
Secondary Outcomes: Psychosocial functioning
Expected Total Enrollment:  498

Study start: December 1999;  Expected completion: December 2010
Last follow-up: December 2009;  Data entry closure: December 2010

CT is a short-term talking therapy that focuses on changing negative thinking patterns and helping patients develop coping skills to deal with their experiences. Evidence suggests that CT is effective in treating a number of psychiatric conditions, including anxiety and anger. This study will determine the effectiveness of CT in treating symptoms of depression.

This study will last approximately 36 months and will comprise three phases. In Phase 1, all participants will receive between 16 and 20 CT sessions for 3 to 4 months. In Phase 2, participants will be randomly assigned to receive additional CT sessions, antidepressants, or placebo for 8 months. Phase 3 is a follow-up period; no treatment will be given in Phase 3. Participants will have study visits once every 4 months for 24 months. Clinician-rated scales and questionnaires will be used to assess depressive symptoms of participants at study start and at the end of each study phase.


Ages Eligible for Study:  18 Years   -   70 Years,  Genders Eligible for Study:  Both

Inclusion Criteria:

  • Have experienced at least two episodes of major depression
  • Have experienced at least one period of recovery during a depressive episode OR have a history of dysthymia (a mood disorder characterized by depression) prior to the onset of current or past depressive episodes
  • Willing and able to comply with all study requirements
  • Able to speak and read English

Exclusion Criteria:

  • Active alcohol or other substance dependence within 6 months prior to study entry
  • Currently at risk for suicide
  • Mood disorders due to a medical condition
  • Bipolar, schizoaffective, obsessive compulsive, or eating disorders
  • Schizophrenia
  • Unable to stop mood-altering medications
  • Current use of medication or diagnosis of a medical disorder that may cause depression
  • Previous failure to experience a reduction in depressive symptoms after 8 weeks of cognitive therapy with a certified therapist
  • Previous failure to experience a reduction in depressive symptoms after 6 weeks of antidepressant treatment
  • Pregnancy or plan to become pregnant during the study or during the year after the study

Location and Contact Information

Please refer to this study by identifier  NCT00118404

      University of Texas Southwestern Medical Center at Dallas, Dallas,  Texas,  75390,  United States; Recruiting
Amy J. McSpadden, BS  214-648-5351 
Robin B. Jarrett, PhD,  Principal Investigator

Study chairs or principal investigators

Robin B. Jarrett, PhD,  Principal Investigator,  University of Texas   

More Information


Hollon SD, Jarrett RB, Nierenberg AA, Thase ME, Trivedi M, Rush AJ. Psychotherapy and medication in the treatment of adult and geriatric depression: which monotherapy or combined treatment? J Clin Psychiatry. 2005 Apr;66(4):455-68. Review.

Jarrett RB, Kraft D, Doyle J, Foster BM, Eaves GG, Silver PC. Preventing recurrent depression using cognitive therapy with and without a continuation phase: a randomized clinical trial. Arch Gen Psychiatry. 2001 Apr;58(4):381-8.

Jarrett RB, Schaffer M, McIntire D, Witt-Browder A, Kraft D, Risser RC. Treatment of atypical depression with cognitive therapy or phenelzine Arch Gen Psychiatry. 2000 Nov;57(11):1084. No abstract available.

Study ID Numbers:  R01-MH058397; R01-MH069619
Record last reviewed:  July 2005
Last Updated:  July 21, 2005
Record first received:  July 8, 2005 Identifier:  NCT00118404
Health Authority: United States: Federal Government processed this record on 2005-07-26

Common Treatments

[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Follow Us